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Pesquisa de mutações nos genes do hormônio antiMülleriano 
(AMH) e do seu receptor (AMHR2) em pacientes com 
síndrome de persistência dos ductos Müllerianos
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ABSTRACT 
Objective: To screen for mutations in AMH and AMHR2 genes in patients with persistent Mülle-
rian duct syndrome (PMDS). Patients and method: Genomic DNA of eight patients with PMDS 
was obtained from peripheral blood leukocytes. Directed sequencing of the coding regions 
and the exon-intron boundaries of AMH and AMHR2 were performed. Results: The AMH mu-
tations p.Arg95*, p.Arg123Trp, c.556-2A>G, and p.Arg502Leu were identified in five patients; 
and p.Gly323Ser and p.Arg407* in AMHR2 of two individuals. In silico analyses of the novel 
c.556-2A>G, p.Arg502Leu and p.Arg407* mutations predicted that they were harmful and were 
possible causes of the disease. Conclusion: A likely molecular etiology was found in the eight 
evaluated patients with PMDS. Four mutations in AMH and two in AMHR2 were identified. 
Three of them are novel mutations, c.556-2A>G, and p.Arg502Leu in AMH; and p.Gly323Ser in 
AMHR2. Arq Bras Endocrinol Metab. 2012;56(8):473-8
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RESUMO
Objetivo: Analisar os genes AMH e AMHR2 em indivíduos com síndrome de persistência dos 
ductos de Müller (SPDM). Pacientes e método: Amostras de DNA genômico de oito pacien-
tes com SPDM foram obtidas de leucócitos de sangue periférico. Sequenciamento direto da 
região codificadora e das áreas intrônicas próximas aos éxons dos genes AMH e AMHR foi 
realizado. Resultados: As mutações p.Arg95*, p.Arg123Trp, c.556-2A>G e p.Arg502Leu no gene 
AMH foram identificadas em cinco pacientes e as mutações p.Gly323Ser e p.Arg407* no gene 
AMHR2, em dois indivíduos. As análises in silico das mutações c.556-2A>G, p.Arg502Leu e 
p.Arg407*, não descritas anteriormente na literatura, previram que elas são deletérias e pos-
sivelmente a causa da doença. Conclusão: Uma provável etiologia molecular foi encontrada 
nos oito pacientes portadores de SPDM avaliados. No gene do AMH foram identificadas quatro 
mutações e no AMHR2, duas mutações. Três das seis mutações encontradas são mutações no-
vas, c.556-2A>G e p.Arg502Leu no gene AMH; e p.Gly323Ser no AMHR2. Arq Bras Endocrinol Metab. 
2012;56(8):473-8
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INTRODUCTION
Normal development of male internal and external genitalia during embryogenesis depends on the 
action of testicular hormones: anti-Müllerian hormone 
(AMH) and testosterone. AMH is secreted by Sertoli 
cells and acts on its receptor in the Müllerian ducts, de-
termining their regression. Testosterone, secreted by 
testicular Leydig cells, acts on the androgen receptor in 
the Wolffian ducts inducing the formation of epidydimis, 
deferent ducts, and seminal vesicles. Testosterone is fur-
ther reduced to dihydrotestosterone (DHT) by the en-
zyme 5α-reductase 2, which acts on the androgen recep-
tor of the prostate and external genitalia, determining 
their masculinization (1). The development of female 
internal genitalia in a male individuals may occur due 
to the incapacity of Sertoli cells to synthesize or secrete 
AMH, or due to alterations in type II AMH receptor.
Patients with persistent Müllerian duct syndrome 
(PMDS) have normal male phenotype, and the presence 
of an uterus and Fallopian tubes is usually discovered 
during corrective surgery for inguinal hernia or crypt-
orchid testis (2). Leydig cell function is preserved, but 
azoospermia is common, due to the malformation of the 
ductus deferens or agenesis of the epididymis (3). The 
testes are usually adhered to the uterine tubes, and may 
be located in the abdominal or inguinal region. Hernia 
uteri inguinalis is a condition where the testes and Mül-
lerian derivatives are found within a hernia inguinalis, 
and when the testes descend through a single inguinal 
canal, this is known as a transverse testicular ectopia. 
The anatomical abnormalities common to all patients 
with PMDS lie in the failure of the gubernaculum to 
anchor the testes in the base of the scrotum. Migration 
of the gubernaculum to the scrotum creates a processus 
vaginalis in which one or both testes, accompanied by 
Müllerian derivatives, may cause hernias (4). Abnormal 
mobility of the testes facilitates their torsion and may 
lead to uni- or bilateral testicular degeneration (3). 
The testes are not often connected to the ejacula-
tory ducts due to aplasia of the epididymis and the up-
per portion of the deferent duct or, secondarily, to the 
disassociation between the epididymis and testis caused 
by the presence of the Müllerian derivatives. The vas 
deferens is generally short and strongly associated with 
the uterine wall. Testicular histology is often normal, 
with the presence of spermatogonia, except in cases of 
long duration cryptorchidism. The presence of testicular 
germ cell tumors in adults patients, sometimes, may lead 
to an unexpected discovery of Müllerian derivatives (5). 
PMDS is a heterogeneous disorder that is inherited 
in a sex-limited autosomal recessive manner. Occur-
rences in several members of some families have already 
been described (6). The phenotype can be produced by 
a mutation in the gene that encodes anti-Müllerian hor-
mone, or by a mutation in type II AMH receptor gene. 
These two forms result in the same phenotype and are 
referred to as PMDS type I and type II, respectively.
The AMH gene was cloned in 1986 by Cate and cols. 
(7). AMH is a small gene containing five exons located in 
chromosome 19p13.3 (8), and its protein product acts 
by means of its specific type II receptor (AMHR2), a ser-
ine/threonine kinase, member of the family of type II re-
ceptors for TGF-b-related proteins (8). Several mutations 
in AMH have already been described (Figure 1) (9-11).
The AMHR2 gene, located in 12q13, was cloned 
in 1994 by two different groups (12,13). AMHR2 
contains 11 exons and more than 27 mutations have 
already been described in this gene (Figure 1) (5,9,14). 
The aim of this study is to screen for mutations in 
AMH and AMHR2 genes in patients with PMDS.
Figure 1. Schematic figure of AMH (A) and AMHR2 (B) genes showing 
the location of the described mutations. 
Missense mutations are shown above the genes. The boxes indicate 
recurrent mutations; gray background designates the mutations identified 
in this study. #: shows the splicing site mutations.
AMH and AMHR2 mutations in PMDS patients
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SUBJECTS AND METHODS
Patients
Eight unrelated patients with PMDS were selected. Five 
patients (patients 1, 2, 3, 4, and 5) were evaluated at the 
Unit of Endocrinology of Development at Hospital das 
Clínicas da Faculdade de Medicina da Universidade de São 
Paulo, and three patients (patients 6, 7 and 8) were evalu-
ated in the Interdisciplinary Group for the Study of Sex 
Determination and Differentiation, Faculdade de Ciên-
cias Médicas da Universidade Estadual de Campinas. Fifty 
five normal males were used as the control group. This 
study was approved by the Ethical Committee of Hospital 
das Clínicas da Faculdade de Medicina da Universidade de 
São Paulo and Faculdade de Ciências Médicas da Univer-
sidade Estadual de Campinas. Written informed consent 
was obtained from all participants of this study. 
Clinical evaluation
The patients presented chronological age from four 
months to 37 years. Four patients reported having con-
sanguineous parents. The main complaints were pres-
ence of inguinal hernia and/or cryptorchidism. All sub-
jects had male external genitalia and uni- or bilateral 
cryptorchidism. Four of them presented inguinal hernia. 
The presence of Müllerian derivatives was de monstrated 
by pelvic ultrasound and/or anatomopathological 
study. AMH levels were determined in three patients: 
64.4 ng/mL in patient 7, and < 0.18 ng/mL in patient 
8 (normal levels for their age: 33.8-110.8 ng/mL). and 
4.6 ng/mL in patient 6 (normal levels for his age: 63.6-
132.2). All of them had 46,XY karyotype.
Molecular evaluation
Genomic DNA samples were obtained from peri pheral 
blood leukocytes using the Salting Out technique 
(15). DNA was amplified by PCR using specific prim-
ers for the AMH (ENSG00000104899) and AMHR2 
(ENSG00000135409) genes (Table 1). All PCR re-
actions were performed with 100-500 ng of genomic 
DNA, 200 mM of dNTP, 20 pmol of each primer, 0.5 
units of Go Taq DNA polymerase (Promega Corpo-
rations, Madison, WI, USA), 50 mM KCl, 1.5 mM 
MgCl2, and 10 mM Tris-HCl at pH 9.0, in a total 
vo lume of 25 mL. PCR conditions were: one cycle of 
95oC for five minutes, 35 cycles consisting of 97oC for 
45 seconds; annealing temperatures (Table 1) for 45 
seconds; 72oC for one or two minutes; and a final cycle 
of 72 oC for 10 minutes. Amplicons were sequenced 
following the protocol of the ABI Prism BigDye Termi-
nator Cycle Sequencing Ready Reaction Kit, and were 
placed in the ABI PRISM 3100 automatic sequencer 
(Life Technologies Corporation, CA, USA).
Cloning: The amplicon of AMH exon 1 was cloned 
into pcDNA3.1/v5-His TOPO TA vector. The TOPO 
10 E. coli were transformed with this vector using pcD-
NA3.1/v5-His TOPO TA Expression Kit (Invitrogen, 
Life Technologies Corporation, CA, USA). Trans-
formed E. coli were grown in selective medium (LB with 
50 µg/mL ampicilin), the vector was extracted with 
QIAprep Spin Miniprep Kit (QIAGEN Inc., Valencia, 
CA, USA), and was sequenced as described above.
In silico analysis: The allelic variants identified were 
analyzed using the software BDGP Splice Site Predic-
tion by Neural Network (http://www.fruitfly.org/
Table 1. Primer sequences, annealing temperatures, and size of amplicons of AMH and AMHR2
Gene exon Forward primer (5’ – 3’) Reverse primer (5’ – 3’) Ann temp (oC) Size (bp)
AMH  1 1F – AAAcAccccAccTTccAcTc 1R – ccggcccAccTgAAggAA 60 530
AMH  2 2F – cAgggAcAgATcccAAAgAT 2R – TAcTgcAgAcccTgcAAcAA 60 288
AMH  3-4 3-4F – gTAgAgcggggcTgggTA 3-4R – cgcAATTggAggAgTTgAgA 57 540
AMH  5 5F – cTggAcAccgTgcccTTc 5R – TggggTccgAATAAATATgg 57 1080
AMHR2  1-2 1-2F – cAggATgcccTgTATcTgAAg 1-2R – acaccccaggatgtgtctgt 58 700
AMHR2  3-4 3-4F – cTcTgTTTccAcAccccATT 3-4R – ggAgAggggTcAgAgcTTTT 58 690
AMHR2  5-6 5-6F – gAcTcccATgAccTcTcAcAA 5-6R – cATgTAgcccccAccTcTAT 58 630
AMHR2  7 7F – ggATggATcAgccgTcTc 7R – AggcAgAATcAcAAAcATAgcA 61 233
AMHR2 8-9 8-9F – AAAAAgAgggAggAAgAAAATc 8-9R – ttggggtgaacctagaatgg 54 670
AMHR2  10 10F – cccTTTcTAcATggTAggcA 10R – AcgTccTTgAAgcccATgcccA 49 267
AMHR2 11 11F – TTTTAAcccTggggcccAcT 11RA – gcAcAccTAccccAAgTcAc 58 524
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seq_tools/splice.html), Mutation Taster (http://www.
mutationtaster.org/), Human Splicing Finder (http://
www.umd.be/HSF/), Polyphen (http://genetics.
bwh.harvard.edu/), and Sift (http://sift.jcvi.org/).
RESULTS
The AMH gene analysis revealed four mutations in five 
patients. Two of them were novel mutations: c.556-
2A>G (intron 2), and p.Arg502Leu (c.1505G>T, exon 
5) (Table 2, Figures 1 and 2). The c.556-2A>G muta-
tion, which involves the acceptor splicing site, was iden-
tified in homozygous state in three patients (1, 2 and 
6). In silico analysis using the software BDGP Splice 
Site Prediction by Neural Network, Mutation Taster, 
and Human Splicing Finder showed that this site is no 
longer recognized as a splicing site, and predicted that 
the mutation was the cause of the disease. Four already 
described allelic variants: c.146 T>G (rs10407022, 
p.Ser49Ile), c.252G>A (rs61736572, p.Leu84=), 
c.303G>A (rs61736575, p.Gly101=), c.555+50G>A 
(rs8112524) were also identified in these patients in ho-
mozygous state. The frequencies of the allelic variants 
c.146 T>G (rs10407022), c.252G>A (rs61736572), 
and c.303G>A (rs61736575) were 23/110 (20.9%), 
2/110 (1.8%) and 2/110 (1.8%), respectively, in the 
normal male group. The homozygous p.Arg502Leu 
(c.1505G>T) mutation was identified in patient 7. Mu-
tation Taster software predicted that this mutation was 
the cause of the disease; Polyphen suggested that this 
mutation was probably harmful, and according to Sift 
software, it would not be tolerated. 
In patient 3, the p.Arg95* (c.283C>T), and 
p.Arg123Trp (c. 367C>T) mutations in exon 1 of 
AMH were detected in compound heterozygous state. 
In silico analysis of p.Arg123Trp mutation using the 
Polyphen software predicted that this variant was prob-
ably a damaging alteration, and Sift software suggested 
a non-tolerated alteration. The p.Arg123Trp mutation 
was also detected in patient 8 in homozygous state.
AMHR2 gene sequencing identified the mutation 
p.Gly323Ser (c.967G>A) and the allelic variants c.424-
30C>T (rs2071557) and c.*13T>C (rs10876455) in 
homozygous state in patient 4. The mutation p.Arg407* 
(c.1219C>T) was found in patient 5 in homozygous 
state. In patients 2 and 3, the heterozygous allelic variant 
c.1038G>A (rs784890, p.Ser346=) was also detected. In 
silico analysis of p.Gly323Ser mutation using Mutation 
Taster and Polyphen software indicated that this altera-
tion was probably damaging and caused the disease.
DISCUSSION
PDMS is one of the rarest causes of development dis-
orders of male internal genitalia, and it is usually diag-
nosed during surgical correction of hernia inguinalis. 
Mutations in AMH or AMHR2 genes, in similar pro-
portions, are the cause of approximately 85% of PMDS 
cases (6,16,17). In the remaining patients, the cause of 
the PMDS is unknown (17).
Patients with AMH or AMHR2 gene mutations 
have no differences in anatomical phenotype. Normal-
ly, AMH levels are measurable during childhood and 
decrease at puberty. Patients with AMH gene defects 
show low AMH levels from birth, whereas patients 
with mutations in AMHR have elevated AMH levels, 
indicating insensitivity of the target tissues (18). At 
Table 2. AMH and AMHR2 gene sequencing results 
Patient AMHmutation State
AMHR2
mutation State
1 c.556-2A>g Homozygous nf -
2 c.556-2A>g Homozygous nf -
3 p.Arg95*
(c. 283c>T)
p.Arg123Trp 
(c. 367c>T)
compound 
Heterozygous
nf -
4 nf - p.gly323Ser
(c.967g>A)
Homozygous
5 nf - p.Arg407*
(c.1219c>T)
Homozygous
6 c.556-2A>g Homozygous nf -
7 p.Arg502Leu
(c.1505g>T)
Homozygous nf -
8 p.Arg123Trp
(c. 367c>T)
Homozygous nf -
nf: not found.
Figure 2. Electropherograms showing the three novel mutations identified 
in this study: A: c.556-2A>g; B: p.Arg502Leu (c.1505g>T); C: 
p.gly323Ser (c.967g>A).
Normal sequences of the genes are shown above and mutated sequences 
are shown below. Arrows indicate nucleotide substitutions.
A B C
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post-pubertal age, AMH levels cannot be used to select 
which gene to study in PMDS patients (3). 
Currently, the majority of AMH mutations de-
scribed are located especially in exon 1, and in the 3’ 
portion of exon 5, which are important regions for 
AMH bioactivity (17). In the present study, the AMH 
p.Arg95*, p.Arg123Trp and p.Arg502Leu mutations 
that were identified were located in these regions, and 
in silico analyses of p.Arg123Trp and p.Arg502Leu 
mutations predicted that they were the genetic causes 
of PMDS in these patients. In addition, Arg502 amino 
acid is conserved in several organisms, showing its im-
portance in this protein.
The p.Arg502Leu mutation was identified in patient 
7, who presented normal levels of AMH for his age, 
indicating that this mutation, because of its position, 
might affect hormone bioactivity, and not its secretion 
rate. Menabo and cols. also described an Italian patient 
with AMH mutations and normal AMH levels (10).
The previously described mutations in AMH, 
p.Arg95* and p.Arg123Trp, were found in compound 
heterozygous state in patient 3, demonstrated by exon 
1 amplicon cloning. The p.Arg95* mutation leads to a 
premature stop codon, resulting in a truncated protein, 
lacking a large part of the normal protein sequence (19). 
Formerly, Imbeaud and cols. described a PMDS patient 
with undetectable AMH levels and p.Arg123Trp muta-
tion (16). These findings were similar to those of pa-
tient 8. 
The novel homozygous c.556-2A>G mutation in 
patients 1, 2, and 6, located in the acceptor splicing 
site, abolished this site according to in silico analysis, 
indicating a possible genetic cause of the disease. Inter-
estingly, these patients had the same three allelic vari-
ants near this mutation, which might indicate a founder 
effect.
AMHR2 mutations were identified in two patients. 
The p.Gly323Ser mutation, present in patient 4, is lo-
cated in exon 7, which is a component of the protein 
kinase domain in the cytoplasmic portion of AMHR2. 
Glycine is a polar and neutral amino acid, and serine is 
a nonpolar and hydrophobic amino acid; these distinct 
amino acid characteristics indicate that the amino acid 
change might affect protein conformation. In addition, 
Gly323 is highly conserved among mammals.
The p.Arg407* mutation leads to a premature stop 
codon. The resulting truncated protein lose a signifi-
cant portion of the serine/threonine kinase domain in 
the intracellular portion of the AMHR responsible for 
the bioactivity of the protein (5). Abduljabbar and cols. 
also identified this mutation in a family from Saudi Ara-
bia that had consanguineous parents and four affected 
males. Molecular models of the intracellular domains 
of the wild type and mutated receptors showed that the 
mutated protein lost most of the αF helix and all of the 
four α-helices at the C terminus (5).
In conclusion, a likely molecular etiology was found 
in these eight patients with PMDS. Four mutations in 
the AMH gene and two in AMHR2 were identified. 
Three of them are novel mutations, c.556-2A>G and 
p.Arg502Leu in AMH; and p.Gly323Ser in AMHR2. 
Further functional studies are necessary to confirm the 
in silico analysis. The possibility of a founder effect of 
the novel AMH mutation (c.556-2A>G) found in three 
Brazilian patients with the PMDS cannot be excluded. 
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